Cited by 125Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.

Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias

Open access

Molinuevo, José L., Lladó, Albert, Rami, Lorena·2005·American Journal of Alzheimer's Disease & Other Dementias®

DOI 10.1177/153331750502000206PMC PMC10833270

Open this paper in CoChat — free account Open PDF

Abstract

The management of dementia has changed since the development of new antidementia drugs. The benefits observed in Alzheimer's disease (AD) with selective cholinergic transmission treatments are mainly symptomatic, without clear evidence of neuroprotection. The hypothesis that glutamate-mediated neurotoxicity is involved in the pathogenesis of AD is finding increasingly more acceptance in the scientific community. Glutamate receptors are overactive, and N-methyl-D-aspartate (NMDA) receptor antagonists have therapeutic potential for the treatment of AD and other neurological disorders. Memantine is a noncompetitive NMDA antagonist that is considered a neuroprotective drug. Memantine's capacity has been demonstrated in preclinical studies, and it is considered a useful symptomatic treatment for AD. Memantine has been shown to benefit cognition, function, and global outcome in patients with moderate to severe AD, and it is currently approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe AD. Recently, memantine has also demonstrated efficacy in the initial stages of AD, although FDA authorization is pending. This review highlights the important pharmacological and clinical aspects of memantine, as well as some basic mechanisms mediating glutamatergic neurodegeneration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/153331750502000206

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Arzneimittelforschung
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,401
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Excitotoxity and the NMDA receptor
Rothman, S. M., & Olney, J. W. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90177-9 · Cited by 1,052
The Biochemistry of Memory: A New and Specific Hypothesis
LYNCH, G. S., & Baudry, M. (1984) · Science · doi:10.1126/science.6144182 · Cited by 1,041
The question of familial meningiomas and schwannomas:
King, A. A., & Gutmann, D. H. (2000) · Neurology · doi:10.1212/wnl.54.1.4 · Cited by 815
Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Excitotoxicity and the NMDA receptor -- still lethal after eight years
Rothman, S. M. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93869-y · Cited by 508

Show all 58 references

Research works printed but not linked: 7

Lobo A, 2000, Neurology, 54, S4
Launer LJ, 2000, Neurology, 54, S1
Kilpatrick GJ, 2002, Curr Opin Investig Drugs, 3, 798
Danysz W, 1995, Drug News Perspect, 8, 261
Landfield PW, 1988, Long-Term Potentiation: A Debate of Current Issues
Pantev M, 1993, Zeitschrift Gentopsychol Psychiatrie, 6, 103
Reisberg B, 2003, Eur Neuropsychopharmacol, 13, S388

Sorted by citations

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Calcium Signaling and Amyloid Toxicity in Alzheimer Disease
Demuro, A., Parker, I., & Stutzmann, G. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.080895 · Cited by 426
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca‐Santos, B., Chorilli, M., & Gremião, M. P. D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 320
Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis
Blaylock, R. L., & Maroon, J. C. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.83391 · Cited by 212
The present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174
Glutamate–glutamine cycling in Alzheimer's disease
WALTON, H., & DODD, P. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.10.007 · Cited by 174
A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence
Buckley, J. S., & Salpeter, S. R. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0266-9 · Cited by 175
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
An update on the novel and approved drugs for Alzheimer disease
Alhazmi, H. A., & Albratty, M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.10.004 · Cited by 122
“Anxiety, emesis, urinary tract infections, and increased sweating were among the less commonly reported symptoms ( Molinuevo et al., 2005 ).”
Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death
Lee, J.-K., Won, J., Singh, A. K., & Singh, I. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.112 · Cited by 104
Apoptotic mechanisms involved in neurodegenerative diseases: Experimental and therapeutic approaches
Camins, A., Pallàs, M., & Silvestre, J. S. (2008) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2008.30.1.1090962 · Cited by 95
Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders
McCarty, M. F. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.01.013 · Cited by 87
Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer’s Disease
Cheng, Y., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052283 · Cited by 89
Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer’s Disease
Baracaldo-Santamaría, D., Avendaño-Lopez, S. S., Ariza-Salamanca, D. F., Rodríguez-Giraldo, M., Calderón‐Ospina, C., González-Reyes, R. E., & Nava-Mesa, M. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109067 · Cited by 86
Protein misfolding in the late‐onset neurodegenerative diseases: Common themes and the unique case of amyotrophic lateral sclerosis
Mulligan, V. K., & Chakrabartty, A. (2013) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24285 · Cited by 81
The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration
Saravi, S. S. S., Saravi, S. S. S., Arefidoust, A., & Dehpour, A. R. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0021-5 · Cited by 77
Effects and possible mechanisms of action of acacetin on the behavior and eye morphology of Drosophila models of Alzheimer’s disease
Wang, X., Perumalsamy, H., Kwon, H. W., Na, Y., & Ahn, Y. (2015) · Scientific Reports · doi:10.1038/srep16127 · Cited by 75
The serotonin 5-HT6receptor: a viable drug target for treating cognitive deficits in Alzheimer’s disease
Geldenhuys, W. J., & der Schyf, C. J. V. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.51 · Cited by 73
A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy
Gadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 71
Memantine Transport across the Mouse Blood–Brain Barrier Is Mediated by a Cationic Influx H + Antiporter
Mehta, D. C., Short, J. L., & Nicolazzo, J. A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400316e · Cited by 60
Pharmacological profile of natural and synthetic compounds with rigid adamantane-based scaffolds as potential agents for the treatment of neurodegenerative diseases
Dembitsky, V. M., Gloriozova, T. A., & Poroikov, V. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.123 · Cited by 61
The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer’s disease
Verma, A., Waiker, D. K., Bhardwaj, B., Saraf, P., & Shrivastava, S. K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105562 · Cited by 58
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 59
Regulation of mitophagy in ischemic brain injury
Yuan, Y., Zhang, X., Zheng, Y., & Chen, Z. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1544-6 · Cited by 58
Alzheimer's disease: Visual system review
Valenti, D. A. (2009) · Optometry · doi:10.1016/j.optm.2009.04.101 · Cited by 60
Persons With Moderate Alzheimer's Disease Improve Activities and Mood via Instruction Technology
Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Sigafoos, J., MT, P., Megna, M., Zonno, N., Martire, M. L. L., Pinto, K., & Minervini, M. G. (2009) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317509332627 · Cited by 51
Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
Sureda, F. X., Junyent, F., Verdaguer, E., Auladell, C., Pelegrí, C., Vilaplana, J., Folch, J., Canudas, A. M., Zárate, C. B., Pallàs, M., et al. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049732 · Cited by 49
Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice
Fertan, E., Stover, K. R., Brant, M. G., Stafford, P. M., Kelly, B., Diez‐Cecilia, E., Wong, A. A., Weaver, D. F., & Brown, R. E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01044 · Cited by 49
Development of an LC–MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study
Bhateria, M., Ramakrishna, R., Pakala, D. B., & Bhatta, R. S. (2015) · Journal of Chromatography B · doi:10.1016/j.jchromb.2015.07.042 · Cited by 46
Persons With Mild or Moderate Alzheimer's Disease Managing Daily Activities via Verbal Instruction Technology
Lancioni, G. E., Martire, M. L. L., Singh, N. N., O’Reilly, M. F., Sigafoos, J., Pinto, K., & Minervini, M. G. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317508328181 · Cited by 46
Neuromodulatory Effect of Thymoquinone in Attenuating Glutamate-Mediated Neurotoxicity Targeting the Amyloidogenic and Apoptotic Pathways
Fouad, I. A., Sharaf, N. M., Abdelghany, R. M., & Sayed, N. S. E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00236 · Cited by 44
Bis(propyl)-cognitin protects against glutamate-induced neuro-excitotoxicity via concurrent regulation of NO, MAPK/ERK and PI3-K/Akt/GSK3β pathways
Hu, S., Cui, W., Mak, S., Tang, J., Choi, C., Pang, Y., & Han, Y. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.022 · Cited by 42
The cellular and pathologic prion protein
Gill, A. C., & Castle, A. R. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63945-5.00002-7 · Cited by 45
Managing Cognitive Dysfunction through the Continuum of Alzheimerʼs Disease
Delrieu, J., Piau, A., Caillaud, C., Voisin, T., & Vellas, B. J. (2011) · CNS Drugs · doi:10.2165/11539810-000000000-00000 · Cited by 44
MECP2 and the biology of MECP2 duplication syndrome
D’Mello, S. R. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15331 · Cited by 42
Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nω-nitro-L-arginine methyl ester
Devan, B. D., Pistell, P. J., Daffin, L. W., Nelson, C. M., Duffy, K. B., Bowker, J. L., Bharati, I. S., Sierra‐Mercado, D., Spangler, E. L., & Ingram, D. K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.008 · Cited by 40
The effects of repeated administrations of MK-801 on ERK and GSK-3β signalling pathways in the rat frontal cortex
Seo, M. S., Kim, S. H., Ahn, Y.-M., Kim, Y., Jeon, W. J., Yoon, S. C., Roh, M., Juhnn, Y., & Kim, Y. S. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006869 · Cited by 40
Anti-BACE1 and Antimicrobial Activities of Steroidal Compounds Isolated from Marine Urechis unicinctus
Zhu, Y.-Z., Liu, J., Wang, X. B., Jeong, I.-H., Ahn, Y., & Zhang, C.-J. (2018) · Marine Drugs · doi:10.3390/md16030094 · Cited by 39
Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform
Kolaj, I., Liyanage, S. I., & Weaver, D. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.001 · Cited by 39
3-Nitropropionic acid toxicity in hippocampus: Protection throughN-methyl-D-aspartate receptor antagonism
Karanian, D. A., Baude, A. S., Brown, Q. B., Parsons, C. G., & Bahr, B. A. (2006) · Hippocampus · doi:10.1002/hipo.20214 · Cited by 39
Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells
Albayrak, G., Konaç, E., Dikmen, A., & Bilen, C. (2017) · Human & Experimental Toxicology · doi:10.1177/0960327117747025 · Cited by 36
Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline
Devan, B. D., Pistell, P. J., Duffy, K. B., Kelley-Bell, B., Spangler, E. L., & Ingram, D. K. (2014) · Neurorehabilitation · doi:10.3233/nre-131022 · Cited by 34
Neuroanatomical abnormalities related to dexamethasone exposure in survivors of childhood acute lymphoblastic leukemia
Phillips, N. S., Cheung, Y. T., Glass, J. O., Scoggins, M., Liu, W., Ogg, R. J., Mulrooney, D. A., Pui, C., Robison, L. L., Reddick, W. E., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27968 · Cited by 34
Glutamatergic dysfunction in neurodegenerative diseases focusing on Parkinson's disease: Role of glutamate modulators
Almohmadi, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Abdelaziz, A. M., Jabir, M. S., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111349 · Cited by 35
p75 NTR Expression is induced in isolated neurons of the penumbra after ischemia by cortical devascularization
Angelo, M. F., Aviles‐Reyes, R. X., Villarreal, A., Barker, P. A., Reinés, A. G., & Ramos, A. J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21993 · Cited by 31
Altered GABAergic neurotransmission is associated with increased kainate-induced seizure in prostaglandin-endoperoxide synthase-2 deficient mice
Toscano, C. D., Ueda, Y., Tomita, Y. A., Vicini, S., & Bosetti, F. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.10.004 · Cited by 33
Stimulating ERK/PI3K/NFκB signaling pathways upon activation of mGluR2/3 restores OGD‐induced impairment in glutamate clearance in astrocytes
Lin, C., You, J., Wei, K., & Gean, P. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12383 · Cited by 30
d-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia
Cheng, Y., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010917 · Cited by 30
Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases
Liu, D., Ander, B. P., & Sharp, F. R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.013 · Cited by 27
Glutamatergic Neurotransmission in Aging and Neurodegenerative Diseases: A Potential Target to Improve Cognitive Impairment in Aging
Castillo-Vázquez, S. K., Massieu, L., Rincón-Heredia, R., la Torre, P. G.-D., Quiroz‐Baez, R., Gómez-Verján, J. C., & Rivero-Segura, N. A. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103039 · Cited by 28
Cell Cycle Inhibition without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: An Update
Liu, D., & Ander, B. P. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/491737 · Cited by 26
Persons with mild and moderate Alzheimer's disease use verbal-instruction technology to manage daily activities: Effects on performance and mood
Lancioni, G., Singh, N., O’Reilly, M., Zonno, N., Flora, A., Cassano, G., De Vanna, F., De Bari, A. L., Pinto, K., & Minervini, M. (2009) · Developmental Neurorehabilitation · doi:10.1080/17518420903029493 · Cited by 26
In vivo [123I]CNS‐1261 binding to D ‐serine‐activated and MK801‐blocked NMDA receptors: A storage phosphor imaging study in rats
Knol, R. J. J., de Bruin, K. M., van Eck‐Smit, B. L. F., Pimlott, S. L., Wyper, D. J., & Booij, J. (2009) · Synapse · doi:10.1002/syn.20629 · Cited by 26
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 25
Glycine/NMDA Receptor Antagonists as Potential CNS Therapeutic Agents: ACEA-1021 and Related Compounds
Cai, S. X. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776894465 · Cited by 25
Pathological Interplay between Inflammation and Mitochondria Aggravates Glutamate Toxicity
Vaglio-Garro, A., Kozlov, A. V., Smirnova, Y. D., & Weidinger, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042276 · Cited by 26
Psychopharmacological Neuroprotection in Neurodegenerative Disease: Heuristic Clinical Applications
Lauterbach, E. C., Shillcutt, S. D., Victoroff, J., Coburn, K. L., & Mendez, M. F. (2010) · Journal of Neuropsychiatry · doi:10.1176/jnp.2010.22.2.130 · Cited by 22
Chronic Traumatic Encephalopathy: The cellular sequela to repetitive brain injury
Vile, A., & Atkinson, L. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.03.035 · Cited by 24
Chronic Traumatic Encephalopathy: A Critical Appraisal
Levin, B., & Bhardwaj, A. (2013) · Neurocritical Care · doi:10.1007/s12028-013-9931-1 · Cited by 22
Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
Hsiung, G. R., & Puangthong, U. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5021 · Cited by 22
Neuro-Metabolite Changes in a Single Season of University Ice Hockey Using Magnetic Resonance Spectroscopy
Panchal, H. V., Sollmann, N., Pasternak, O., Alosco, M. L., Kinzel, P., Kaufmann, D., Härtl, E., Forwell, L. A., Johnson, A. M., Skopelja, E. N., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00616 · Cited by 22
Altered mRNA Editing and Expression of Ionotropic Glutamate Receptors after Kainic Acid Exposure in Cyclooxygenase-2 Deficient Mice
Caracciolo, L., Barbon, A., Palumbo, S., Mora, C., Toscano, C. D., Bosetti, F., & Barlati, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019398 · Cited by 22
Clavulanic Acid: A Novel Potential Agent in Prevention and Treatment of Scopolamine-Induced Alzheimer’s Disease
Anoush, M., Pourmansouri, Z., Javadi, R., GhorbanPour, B., Sharafi, A., Mohamadpour, H., Anarkooli, I. J., & Andalib, S. (2022) · ACS Omega · doi:10.1021/acsomega.2c00231 · Cited by 21
Determining the effect of aging, recovery time, and post-stroke memantine treatment on delayed thalamic gliosis after cortical infarct
Kim, G. S., Stephenson, J. M., Mamun, A. A., Wu, T., Goss, M. G., Min, J., Li, J., Liu, F., & Marrelli, S. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-91998-3 · Cited by 23
Memantine abrogates testicular dysfunction induced by risperidone in rats with a potential role of ERK1/2-Nrf2-caspase-3 signaling pathway
Mohyeldin, R. H., Sharata, E. E., Fawzy, M. A., Attya, M. E., Welson, N. N., & Rofaeil, R. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-94760-1 · Cited by 19
Anti-N-Methyl-D-Aspartic Acid Receptor 2 (Anti-NR2) Antibody in Neuropsychiatric Lupus Serum Damages the Blood–Brain Barrier and Enters the Brain
Wang, J., Zhao, Y., Zhang, J., & Lei, H. (2019) · Medical Science Monitor · doi:10.12659/msm.912389 · Cited by 18
Current Drug Targets in Alzheimer’s Associated Memory Impairment: A Comprehensive Review
Chandrashekar, K. S., Mathew, A., Vignesh Balaji, E., Pai, K. S. R., Kishore, A., Pai, V., & Pemmireddy, R. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220401124719 · Cited by 18
Novel therapeutic strategies in glioma targeting glutamatergic neurotransmission
Kumaria, A., & Ashkan, K. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148515 · Cited by 20
The multifactorial role of vanillin in amelioration of aluminium chloride and D-galactose induced Alzheimer's disease in mice
Anand, A., Khurana, N., Kaur, S., Ali, N., Alasmari, A. F., Waseem, M., Iqbal, M., Alzahrani, F. M., & Sharma, N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175832 · Cited by 18
Biatractylolide Modulates PI3K‐Akt‐GSK3 β ‐Dependent Pathways to Protect against Glutamate‐Induced Cell Damage in PC12 and SH‐SY5Y Cells
Zhu, L., Ning, N., Yu, L., Zhang, Q., Xie, Y., Irshad, M., Feng, X., & Tao, X. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/1291458 · Cited by 18
Persons with Alzheimer's disease perform daily activities using verbal-instruction technology: A maintenance assessment
Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Zonno, N., Cassano, G., Vanna, F. D., Bari, A. L. D., Pinto, K., & Minervini, M. G. (2010) · Developmental Neurorehabilitation · doi:10.3109/17518420903468480 · Cited by 17
Protective role of amantadine in mitochondrial dysfunction and oxidative stress mediated by hepatitis C virus protein expression
Quarato, G., Scrima, R., Ripoli, M. C., Agriesti, F., Moradpour, D., Capitanio, N., & Piccoli, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.03.018 · Cited by 16
Immunoexcitotoxicity as a Central Mechanism of Chronic Traumatic Encephalopathy – A Unifying Hypothesis
Blaylock, R. L., & Maroon, J. C. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734745-00045 · Cited by 16
Memantine can relieve the neuronal impairment caused by neurotropic virus infection
Sun, L., Zhou, M., Liu, C., Tang, Y., Xiao, K., Dai, J., Gao, Z., Siew, L., Cao, G., Wu, X. Y., et al. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25396 · Cited by 15
Smartphone based TLC approach versus conventional densitometric measurement for the simultaneous determination of donepezil and memantine, content uniformity testing along with greenness and whiteness assessment
Moaaz, E. M., Abdel‐Moety, E. M., Rezk, M. R., & Fayed, A. S. (2024) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2024.101789 · Cited by 14
Innovative sensors with selectivity enhancement by molecularly imprinted polymers for the concurrent quantification of donepezil and memantine
Moaaz, E. M., Fayed, A. S., Abdel‐Moety, E. M., & Rezk, M. R. (2025) · RSC Advances · doi:10.1039/d5ra02850g · Cited by 15
Influx Transport of Cationic Drug at the Blood–Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants
Kubo, Y., Akanuma, S., & Hosoya, K. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00090 · Cited by 13
Reduced CNS exposure of memantine in a triple transgenic mouse model of Alzheimer's disease assessed using a novel LC–MS technique
Mehta, D. C., Short, J. L., & Nicolazzo, J. A. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.07.027 · Cited by 12
Recent Modifications of Anti-dementia Agents Focusing on Tacrine and/or Donepezil Analogs
Mohamed, L. W., Mohamed, K. O., Sayed, H. S., & Mahmoud, Z. (2022) · Medicinal Chemistry · doi:10.2174/1573406418666220827155615 · Cited by 12
Uptake Study in Lysosome-Enriched Fraction: Critical Involvement of Lysosomal Trapping in Quinacrine Uptake but Not Fluorescence-Labeled Verapamil Transport at Blood-Retinal Barrier
Kubo, Y., Yamada, M., Konakawa, S., Akanuma, S., & Hosoya, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080747 · Cited by 11
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia
Souchet, B., Audrain, M., Alves, S., Fol, R. R., Tada, S., Orefice, N. S., Potier, B., Dutar, P., Billard, J., Cartier, N., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.67 · Cited by 9
Therapeutic Effects of Thymoquinone on Alzheimer’s Disease through Modulating Amyloid-beta Neurotoxicity and Neuro-inflammatory Cytokine Levels
Alasmari, F. F., Alotaibi, F. M., Al-Qahtani, W. S., Alasmari, A. F., & Alqahtani, F. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220418125057 · Cited by 9
Reduction in the protein level of c-Jun and phosphorylation of Ser73–c-Jun in rat frontal cortex after repeated MK-801 treatment
Ahn, Y. M., Seo, M. S., Kim, S. H., Jeon, W. J., Kim, Y., Kang, U. G., Juhnn, Y., & Kim, Y. S. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2007.12.013 · Cited by 9
Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
Zhang, Y., Li, S., Wang, Y., Deng, G., Cao, N., Wu, C., Ding, W., Wang, Y., Cheng, X. M., & Wang, C. (2019) · Molecules · doi:10.3390/molecules24071430 · Cited by 9
Calpain Interactions with the Protein Phosphatase Calcineurin in Neurodegeneration
Norris, C. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9099-9_2 · Cited by 8
Pharmacokinetic Drug-Drug Interaction and Responsible Mechanism between Memantine and Cimetidine
Choi, Y. A., Song, I., & Choi, M. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030119 · Cited by 8
Neurodegeneration
Bozyczko‐Coyne, D., & Williams, M. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00168-1 · Cited by 8
Factors Associated with Cognitive Decline in Transient Ischemic Attack Patients
Sivakumar, L., Camicioli, R. M., & Butcher, K. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100017248 · Cited by 8
Apoptosis: Pathways, Molecules and Beyond
Singh, N., & Bose, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-19497-4_1 · Cited by 7
Protracted exposure to supraphysiological levels of corticosterone does not cause neuronal loss or damage and protects against kainic acid-induced neurotoxicity in the hippocampus of C57BL/6J mice
Benkovic, S. A., O'Callaghan, J. P., & Miller, D. B. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.07.005 · Cited by 6
Reactive Astrocytes with Reduced Function of Glutamate Transporters in the App NL-G-F Knock-in Mice
Srivastava, I., Goikolea, J., Kaya, T. A., Latorre‐Leal, M., Eroli, F., Iglesias, M. P., Álvarez-Jiménez, L., Arroyo‐García, L. E., Shimozawa, M., Nilsson, P., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00714 · Cited by 8
Alzheimer's disease
Delrieu, J. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch63 · Cited by 4
Combined Preventive and Preconditioning Treatments for the Comorbidity of Alzheimer’s Disease and Ischemic Stroke in a GluN3A Knockout Mouse and a 5xFAD Mouse
Yu, S. P., Gu, X., Jiang, M. Q., Sastry, A., Wu, L., Li, Y., & Wei, L. (2025) · Cells · doi:10.3390/cells14231871 · Cited by 3
Paeonol Derivative, 6′-Methyl Paeonol, Attenuates Aβ-Induced Pathophysiology in Cortical Neurons and in an Alzheimer’s Disease Mice Model
Chen, P., Yao, C., Chien, P., Tsai, H.-J., Chen, Y., Chuang, J.-H., Chou, P.-L., Lee, G.-C., Lin, W., & Lin, Y. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00633 · Cited by 3
Design, Synthesis and Biological Evaluation of Novel Adamantane Derivatives as Potential Treatments for Alzheimer’s Disease
Shakeri, A. (2017) · UWSpace (University of Waterloo) · Cited by 2
Evaluation of SK-N-SH Cells as a Model for NMDA Receptor Induced Toxicity
Schreiber, J. A., & Goerges, G. (2024) · Cellular Physiology and Biochemistry · doi:10.33594/000000722 · Cited by 2
Effectiveness of neuro-feedback on Alzheimer’s rehabilitation: a bibliometric analysis
Verma, S., & Kurdekar, A. D. (2024) · Neurodegenerative Disease Management · doi:10.1080/17582024.2024.2435250 · Cited by 2
In silico analysis of binding interaction of phytoconstituents with N-methyl-D-aspartate receptor for potential therapeutic use in Alzheimer's disease
Kumar, S., & Chowdhury, S. (2018) · Pharmacognosy Magazine · doi:10.4103/pm.pm_214_18 · Cited by 2
Chromatographic Framework to Determine the Memantine Binding Mechanism on Human Serum Albumin Surface
Ibrahim, F., Guillaume, Y. C., & André, C. (2008) · Chromatographia · doi:10.1365/s10337-008-0675-6 · Cited by 2
Protein Misfolding, Neurodegeneration and Tau
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800186-8.00001-8 · Cited by 2

Authors: Molinuevo, J. L., Lladó, A., & Rami, L.
Affiliations: Hospital Clínic de Barcelona (ES)
ORCID: Molinuevo, José L.
Lladó, Albert
Rami, Lorena
Venue: American Journal of Alzheimer's Disease & Other Dementias®
Publisher: SAGE Publications
Published: 2005-03
Volume: 20
Issue: 2
Pages: 77-85
ISSN: 0888-4897 (ISSN-L)
1533-3175
1938-2731
DOI: 10.1177/153331750502000206
PMC: PMC10833270
OpenAlex: W2140959932
Cited by: 125
References: 58
Citations by year: 2026: 3 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 2 · 2015: 8 · 2014: 5 · 2013: 8 · 2012: 4
FWCI: 3.40
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: memantine, Alzheimer's disease, dementia, glutamate excitotoxicity, NMDA receptor antagonists, neuroprotection, symptomatic treatment, clinical efficacy
MeSH terms: Animals, Clinical Trials as Topic, Dementia, Drug Evaluation, Preclinical, Humans, Memantine, Molecular Structure, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Glutamic Acid, Amino Acid Transport System X-AG

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks